Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05042193 · ClinicalTrials.gov registry record

A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19

A clinical trial, sponsored by Everly Health.

Completed
Registry status
1,883
Enrollment target

NCT05042193 is a clinical trial that has completed, run by Everly Health. The registered enrollment target is 1,883 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05042193 has completed, sponsored by Everly Health.

COMPLETED
Registry status
1,883 participants
Enrollment target

Study Summary

The primary objective of this study is to describe the longevity of IgG against SARS-CoV-2 infection or vaccination.

Interventions

  • OTHER SARS-CoV-2

Trial Details

FieldValue
Enrollment Target 1,883 participants
Start Date 2021-03-19
Est. Completion 2022-06-14

Sponsor

Everly Health

2 total trials

What the Registry Record Tells You About NCT05042193

The ClinicalTrials.gov registry entry for NCT05042193 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,883 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Everly Health, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which SARS-CoV-2 is the first listed.

NCT05042193 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05042193 about?

NCT05042193 is a clinical study titled "A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19". The primary objective of this study is to describe the longevity of IgG against SARS-CoV-2 infection or vaccination.

What is the current status of trial NCT05042193?

This trial is currently completed. The enrollment target is 1,883 participants. The study started on 2021-03-19. Estimated completion is 2022-06-14.

What interventions are being tested in trial NCT05042193?

The interventions under investigation include: SARS-CoV-2 (OTHER).

Who is sponsoring clinical trial NCT05042193?

This trial is sponsored by Everly Health, which has 2 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.